Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

COVID Lockdowns Significantly Increasing Children's Vitamin D Deficiency?

2.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

3.

The need for more Latinx participants in Alzheimer's trials is urgent.

4.

Prostate cancer therapies: AI-based image analysis detects early organ damage

5.

For MDS-Related Anemia, Telomerase Inhibitor Approved.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot